#USA #Paris #Personalized Medicine #Theranostics #DOSIsoft

Unveiling a New Era in Theranostics

In a significant advancement for personalized nuclear medicine, DOSIsoft, a leading provider of dosimetry software for radio-oncology and nuclear medicine, has introduced DOSIsoft Theranostics. This newly established entity is dedicated to enhancing the development of theranostic software, aiming to broaden its clinical application. By intertwining diagnostic insights with targeted therapies, theranostics promises to revolutionize patient treatment and care.

Expanding Clinical Possibilities

DOSIsoft Theranostics is strategically positioned to serve the clinical and industrial ecosystems as a neutral software partner. This independence enables the organization to drive innovation while fostering long-term alliances and investments. The move comes at a time when theranostics is entering a climactic phase of clinical and industrial growth, highlighting the need for advanced solutions.

Leveraging over twenty years of expertise, DOSIsoft Theranostics aims to accelerate the innovation of software solutions that support radiopharmaceutical therapies and improve nuclear medicine practices. These innovations include the implementation of AI-driven workflows and the provision of personalized care.

The Role of PLANET® Software

At the heart of DOSIsoft Theranostics lies PLANET®, the flagship software platform. Originally designed for external beam radiotherapy treatment planning, PLANET® has undergone substantial evolution into a comprehensive platform that offers advanced voxel-based multi-radionuclide dosimetry and full DICOM interoperability. This robust software has received FDA 510(k) approval and CE marking, allowing its adoption in prestigious hospitals and research centers worldwide. Furthermore, its vendor-independent architecture provides specialists with the flexibility to adapt to diverse clinical workflows and therapeutic strategies.

Commitment to Innovation

Marc Uszynski, CEO of DOSIsoft, stated, “The establishment of a dedicated organization for theranostics reflects our long-term commitment to this rapidly expanding field. It provides DOSIsoft Theranostics with the strategic focus and agility necessary to accelerate innovation, foster new partnerships, and expand theranostic applications globally.” This sentiment underscores the organization's intent to drive not just innovation but also industry-wide collaboration.

DOSIsoft Theranostics will make its debut at the upcoming SNMMI 2026 conference, signaling its commitment to be at the forefront of discussion and development within the theranostics community.

A Legacy of Excellence

Founded in 2002, DOSIsoft has firmly established itself as a frontrunner in dosimetry software for nuclear medicine and radio-oncology, dedicated to improving treatment quality and patient safety. With over a thousand installations across 800 hospitals in 80 countries, DOSIsoft continues to deliver cutting-edge solutions for quality control in radiotherapy, theranostics, and personalized dosimetry. As a spin-off from renowned institutions like Gustave Roussy and Institut Curie, DOSIsoft maintains a robust partnership with leading global cancer centers through projects such as the European Thera4Care initiative.

Conclusion

The launch of DOSIsoft Theranostics marks a pivotal step towards advancing personalized medicine through innovative software solutions. With a commitment to improving patient outcomes and an eye on future technology, DOSIsoft Theranostics is poised to play a crucial role in the ever-evolving landscape of theranostics and nuclear medicine.